AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 99 filers reported holding AKERO THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $64,828,892 | +1053.2% | 1,281,710 | +964.5% | 0.03% | +1300.0% |
| Q2 2023 | $5,621,709 | +98.9% | 120,405 | +63.0% | 0.00% | +100.0% |
| Q1 2023 | $2,827,031 | +49.2% | 73,890 | +113.7% | 0.00% | 0.0% |
| Q4 2022 | $1,894,984 | +126.9% | 34,580 | +41.0% | 0.00% | – |
| Q3 2022 | $835,000 | +313.4% | 24,528 | +14.6% | 0.00% | – |
| Q2 2022 | $202,000 | -11.0% | 21,400 | +33.8% | 0.00% | – |
| Q1 2022 | $227,000 | -32.8% | 16,000 | 0.0% | 0.00% | – |
| Q4 2021 | $338,000 | -5.6% | 16,000 | 0.0% | 0.00% | – |
| Q3 2021 | $358,000 | -23.7% | 16,000 | -15.3% | 0.00% | – |
| Q2 2021 | $469,000 | +10.1% | 18,900 | +28.6% | 0.00% | – |
| Q1 2021 | $426,000 | -3.0% | 14,700 | -13.5% | 0.00% | – |
| Q4 2020 | $439,000 | -23.8% | 17,000 | -9.1% | 0.00% | – |
| Q3 2020 | $576,000 | +4.5% | 18,700 | -15.4% | 0.00% | – |
| Q2 2020 | $551,000 | +83.1% | 22,100 | +55.6% | 0.00% | – |
| Q1 2020 | $301,000 | – | 14,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
| venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
| Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
| Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
| Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
| Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
| Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
| Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
| HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |